Dapagliflozin met primary endpoint in DELIVER Phase III trial
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Acute asthma attack is a common cause of admission to emergency departments (EDs) among children, and triage by severity is important for determining appropriate clinical treatment
The technology was able to identify approximately 32 percent more adenomas than standard colonoscopy procedures
A total of five observations for Goa and 17 for Monroe
Investment with representation on the Board of Directors and technical know-how
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU
The new lab is a testament to the Pondicherry Institute of Medical Sciences (PIMS)’s long-held values and traditions of striving for excellence and embracing newer innovations in order to deliver the best standard of training for their students
The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
Subscribe To Our Newsletter & Stay Updated